NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 22 Jul 2019 (#24)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit **www.grants.nih.gov** or **www.sun.ac.za/RDSfunding** (current & archive).*

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- **Refresher on Federal Law and NIH Policy on Select Agents**
  It's not unusual for NIAID-funded research to include organisms that pose a significant public health risk. These pathogens have been designated as select agents by HHS and require additional safety precautions. Before you apply for NIAID funding, you should know whether your research involves select agents, and if it does, the steps you will need to take to ensure public health safety, which are outlined in the Federal Select Agent Program (link is external). Check the **Select Agents and Toxins List (link is external)**

- Take note if your research involves tuberculosis (TB): NIAID reissued a funding opportunity announcement titled **Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals To Inform Innovative Tuberculosis Vaccine Design (R01, Clinical Trial Not Allowed) (link is external).** This program announcement will support innovative studies to identify and understand protective immune responses against *Mycobacterium tuberculosis* (*Mtb*) infection or progression to active TB disease.

1. Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** PAR-19-307 **Type: R01**
Application Due Date: January 14, 2020, January 14, 2021, and January 14, 2022. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immune responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational TB vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals. Research supported under this FOA should go beyond descriptive information currently known about Mtb infection, immune responses to TB vaccines, or immune modulation by non-tuberculous mycobacterial (NTM) infection, or by HIV/AIDS. Applications are sought that include characterization of the timing, anatomical location, and contribution to disease outcome, of mucosal and/or systemic immune responses to mycobacterial infection and/or vaccination. This research is expected to advance understanding of immune mechanisms in Mtb infection/vaccination and contribute to the advancement of new TB vaccines, including in populations also infected with HIV.
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Notice of Special Interest (NOSI): Accelerate Dissemination of Emerging Glycoscience Tools through Collaborations Between Developers and Early Adopters

Letter of Intent: 30 days prior to the application due date **Hyperlink: NOT-RM-19-012** **Type:**
Application Due Date: Standard dates and Standard AIDS dates. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: Glycans are saccharides that can be attached to a wide variety of biological molecules to augment their function. They play important roles in virtually all biological processes including early development, immune regulation, disease processes, and vaccine development. Often, glycans are the predominant molecule on the cell surface and serve as the first point of contact between cells, the extracellular matrix and pathogens. Although carbohydrates play important roles in both normal and disease processes, their complexity presents challenges to their study by most biomedical researchers. To encourage broad adoption of CF-GSP tools/technologies, the Common Fund will support administrative supplements to NIH-supported investigators who are NOT part of the Glycoscience program and NOT established glycoscientists. These will be one-year administrative supplements to existing NIH awards for:

- Non-specialists who need access to glycobiology tools
- Engaging core facilities to adopt glyco tools/technologies developed by the CF-GSP
- Intensive collaboration between CF-GSP technology/methodology developers and non-glycoscientist adopters
- Validation and refinement of CF-GSP technologies and methodologies
- Faster demonstration of effectiveness of CF-GSP technologies and methodologies
- Feedback for documentation and tutorials related to the technologies and methodologies developed by the CF-GSP

Budget: To be eligible, the parent award must be able to receive funds in FY19 (Oct. 1, 2018- Sept. 30, 2019) and not be in a no-cost extension period at the time of the award. One-time supplement budget requests cannot exceed $100,000/year direct costs. It is anticipated that 3-5 awards will be made, subject to availability of funds in FY2019.

Brief definitions of some NIH grant mechanisms: ***comprehensive list of extramural grant and cooperative agreement activity codes***

Research Development and Support Division (RDSD), **Faculty of Medicine and Health Sciences, Stellenbosch University** 5th Floor, Teaching Block, Tygerberg Campus. Enquiries: ***Christa*** e: **cdevries@sun.ac.za** | t: +27 21 938 9838	**Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)** **Stellenbosch University** 2038 Wilcocks Building, Ryneveld Street Enquiries: ***Lizél*** e: **lizelk@sun.ac.za** | t: +27 21 808 2105